BioSig Technologies, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (NASDAQ: BSGM) on July 1, 2021, reporting events that occurred on June 30, 2021. The company is incorporated in Delaware and operates with principal executive offices in Westport, Connecticut. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and board composition rather than financial performance.
Material Changes
The primary material change reported is the departure of Jeffrey F. O'Donnell, Sr. from the Board of Directors, effective immediately on June 30, 2021. The resignation was not connected to any dispute regarding the Company's operations, policies, or practices. Concurrent with his departure, the Company entered into a new contractual arrangement with Mr. O'Donnell.
Management Commentary, Risks, and Unusual Items
Management confirmed the resignation was amicable. As part of the transition, the Company implemented the following compensatory arrangements for Mr. O'Donnell:
- Granted 16,310 fully vested shares of restricted common stock for 2021 Board service.
- Accelerated vesting of 50,000 previously awarded restricted stock units.
- Amended outstanding option awards with the Company and its majority-owned subsidiary, ViralClear Pharmaceuticals, Inc., to extend exercisability periods.
- Removed forfeiture contingencies associated with restricted stock units in ViralClear.
- Executed a 12-month Availability Retainer Agreement providing a monthly base salary of $17,000 for up to 20 hours of services per month on an as-needed basis. Payments are guaranteed regardless of actual hours worked.
Investor Verification Checklist
- Verify the impact of the $17,000 monthly retainer on future operating expenses.
- Confirm the total equity value granted via the 16,310 new shares and 50,000 accelerated RSUs.
- Review the Company's plan to fill the vacancy on the Board of Directors.
- Assess the strategic necessity of retaining Mr. O'Donnell for scientific and strategic guidance post-resignation.